- Conditions
- Head and Neck Cancer
- Interventions
- radiation combined with weekly carboplatin, conservation surgery
- Other · Procedure
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1657–1680
of 1,787
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
- Interventions
- Osimertinib, Osimertinib + Chemotherapy
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
- Interventions
- Capecitabine, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 1023
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 634 more
- Conditions
- Head and Neck Cancer
- Interventions
- chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Drug · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2013
- U.S. locations
- 22
- States / cities
- Tampa, Florida • Atlanta, Georgia • Decatur, Georgia + 17 more
- Conditions
- Head and Neck Cancer
- Interventions
- filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Advanced Cervical Carcinoma, Cervical Cancer, Cervix Cancer, Cancer of the Cervix
- Interventions
- Telaglenastat, Radiation treatment, Cisplatin
- Drug · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma
- Interventions
- VS-101, Cisplatin, Radiation
- Drug · Radiation
- Lead sponsor
- VSPharmTech Co.,Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Manhattan, New York
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- Nivolumab, Pemetrexed, Cisplatin or Carboplatin
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Cancer
- Interventions
- urine samples (biomarkers), blood samples (biomarkers), blood sample (DNA)
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Adenocarcinoma AJCC v7, Stage III Lung Large Cell Carcinoma AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Adenocarcinoma AJCC v7, Stage IIIA Lung Large Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Adenocarcinoma AJCC v7, Stage IIIB Lung Large Cell Carcinoma AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Adenocarcinoma AJCC v7, Stage IV Lung Large Cell Carcinoma AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
- Interventions
- 3-Dimensional Conformal Radiation Therapy, Cisplatin, Intensity-Modulated Radiation Therapy, Methoxyamine, Methoxyamine Hydrochloride, Pemetrexed, Pemetrexed Disodium
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Squamous Cell Carcinoma of the Head and Neck T1/2N0-2
- Interventions
- Intensity Modulated Radiotherapy
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Interventions
- vorinostat, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Thalidomide, Ara-C, BCNU, Cisplatin, Cytoxan, Dexamethasone, Doxorubicin, Etoposide, Filgrastim, Recombinant GM-CSF, Interferon-alpha-2b, Melphalan, Vincristine
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2014
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Mesothelioma
- Interventions
- Pleurectomy/Decortication, pemetrexed and cisplatin or carboplatin, Intensity Modulated Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 12
- States / cities
- Tampa, Florida • Boston, Massachusetts • Rochester, Minnesota + 9 more
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Human Papillomavirus-Positive Squamous Cell Carcinoma
- Interventions
- Transoral Surgery, External Beam Radiation Therapy, Cisplatin, Incisional Tumor Biopsy, Circulating tumor deoxyribonucleic acid (ctDNA) levels assessment, MD Anderson Dysphagia Index, University of Washington Quality of Life Questionnaire, Euro-QOL 5 dimension scale questionnaire, Modified barium swallow (MBS) evaluation with aspiration-penetration scale
- Procedure · Radiation · Drug + 2 more
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Newark, New Jersey
- Conditions
- Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
- Interventions
- Radiation Therapy, Cetuximab, Chemotherapy, Immunotherapy
- Radiation · Drug
- Lead sponsor
- Loren Mell, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 2
- States / cities
- La Jolla, California
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Tislelizumab, Concurrent chemoradiotherapy (cCRT), Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Jacksonville, Florida • Winter Haven, Florida + 11 more
- Conditions
- Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Interventions
- Nivolumab, Relatlimab, Carboplatin, Cisplatin, Paclitaxel, Nab-Paclitaxel, Pemetrexed
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 468 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Duarte, California • Orange, California • New Haven, Connecticut + 25 more
- Conditions
- Advanced Solid Tumors
- Interventions
- GS-3583, Zimberelimab, Cisplatin, Carboplatin, 5-Fluorouracil, Docetaxel
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Grand Rapids, Michigan • New York, New York • Portland, Oregon + 1 more
- Conditions
- Endometrial Cancer
- Interventions
- Trastuzumab Deruxtecan, Chemotherapy
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 14
- States / cities
- Fort Lauderdale, Florida • Miami, Florida • Miami Beach, Florida + 10 more
- Conditions
- Testicular Germ Cell Tumor
- Interventions
- EORTC QLQ-CIPN20
- Other
- Lead sponsor
- Costantine Albany
- Other
- Eligibility
- 15 Years and older · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Rochester, Minnesota
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- TLK286, cisplatin
- Drug
- Lead sponsor
- Telik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Nashville, Tennessee • Houston, Texas
- Conditions
- Oral Squamous Cell Carcinoma
- Interventions
- PRV211 (Intraoperative Cisplatin System), PRV111 (Cisplatin Transmucosal System), PRV131 (Cisplatin Intratumoral Injectable)
- Drug
- Lead sponsor
- Privo Technologies
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 4
- States / cities
- Duarte, California • Miami, Florida • Chicago, Illinois + 1 more
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Clinical Observation, Computed Tomography, Crizotinib, Cytology Specimen Collection Procedure, Echocardiography Test, Erlotinib, Gemcitabine Hydrochloride, Nivolumab, Paclitaxel, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Placebo Administration, Positron Emission Tomography
- Procedure · Drug · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7,458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1655
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 1013 more